Serum uric acid: Marker for atherosclerosis as it is positively associated with "atherogenic index of plasma"

Archives of Physiology and Biochemistry

Volumn 119, Issue 1, 2013, Pages 27-31

  Baliarsingh, Simant ^a   Sharma, Neha ^a   Mukherjee, Ranadip ^a  

^a SRMS Institute of Medical Sciences   (India)

Author keywords

LDL C HDL C; TC HDL C; Total cholesterol

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD; DIAGNOSTIC KIT; DYSLIPIDEMIA; HUMAN; INDIA; MALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; INDIA; MALE; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; RETROSPECTIVE STUDIES; RISK FACTORS; URIC ACID;

EID: 84873327757     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2012.732580     Document Type: Article

References (29)

1. Austin MA, King MC, Vranizan KM, Krauss RM. (1999). Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82:495-506.
2. Baliarsingh S, Sharma N. (2012). Serum uric acid level is an indicator of total cholesterol and low density lipoprotein cholesterol in men below 45 years in age but not older males. Clin Lab 58(5-6):545-50.
3. Bjornheden T, Babyi A, Bondjers G, Wiklund O. (1996). Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123:43-56.
4. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, Burnier M. (2004). Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 4:9.
5. Dobiásová M. (2006). AIP-atherogenic index of plasma as a signifcant predictor of cardiovascular risk: from research to practice. Vnitr Lek 52(1):64-71.
6. Dobiásová M, Frohlich J. (2001). Te plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterifcation rate in apo B-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 34(7):583-88.
7. Dobiásová M, Raslova K, Rauchova H, Vohnout B, Ptackova K, Frohlich J. (2001). Atherogenic lipoprotein profle in families with and without history of early myocardial infarction. Physiol Res 50: 1-8.
8. Fang J, Alderman MH. (2000). Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283(18):2404-10.
9. Friedewald WT, Levy RI, Fredrickson DS. (1972). Estimation of the concentration of LDL cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 18:499-502.
10. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. (1998). Small dense low density lipoprotein has increased afnity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 39:1263-73.
11. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. (1997). Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. Circulation 96:2520-25.
12. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. (2005). Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Tromb Vasc Biol 25(5):1038-44.
13. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. (2003). Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41(6):1183-90.
14. Kackov S, Simundi? AM, Nikolac N, Bilusi? M. (2011). Te association of uric acid with glucose and lipids in general population: Croatian cross-sectional study. Coll Antropol 35(4):1055-9.
15. Keating GM, Croom KF. (2007). Fenofbrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67(1):121-53.
16. Lamarche B, St-Pierre AC, Ruel IL, Cantin B, Dagenais GR, Després JP. (2001). A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 17(8):859-65.
17. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, Dagenais GR, Després JP. (2001). Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/ HDL cholesterol ratio as indices of ischemic heart disease in men: the Quebec Cardiovascular Study. Arch Itern Med 161(22):2685-92.
18. Li Y, Stamler J, Xiao Z, Folsom A, Tao S, Zhang H. (1997). Serum uric acid and its correlates in Chinese adult populations, urban and rural, of Beijing. Int J Epidemiol 26(2):288-96.
19. Liu ML, Ylitalo K, Nuotio I, Salonen R, Salonen JT, Taskinen MR. (2002). Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke 33(5):1255-60.
20. Liu ML, Ylitalo K, Vakkilainen J, Nuotio I, Valkonen M, Lahdenperä S, Viikari J, Taskinen MR. (2002). Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with diferent lipid phenotypes. Ann Med 34(1):48-54.
21. Mendis S, Puska P, Norrving B. (2011) Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization.
22. Nwagha UI, Igweh JC. (2005). Atherogenic Index of Plasma: A signifcant indicator for the onset of Atherosclerosis during menopause in hypertensive females of South East Nigeria. Journal of College of Medicine 10(2):67-71.
23. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, Elisaf MS. (2008). Te efect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 24(7):1919-29.
24. Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT. (2004). Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164(14):1546-51.
25. Rizzo M, Berneis K. (2005). Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Tromb 12(5):237-9.
26. Rizzo M, Bernies K. (2006). Low-density lipoprotein size and cardiovascular risk assessment. Q J Med 99:1-14.
27. Russo C, Olivieri O, Girelli D, Guarini P, Corrocher R. (1996). Relationships between serum uric acid and lipids in healthy subjects. Prev Med 25(5):611-6.
28. Yang D, Liu X, Xiang M. (2001). Te correlation between lipids ratio and degree of coronary artery stenosis. High Blood Press Cardiovasc Prev 18(2):53-6.
29. Zoppini G, Targher G, Negri C, Stoico V, Perrone F, Muggeo M, Bonora E. (2009). Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care 32(9):1716-20.